Literature DB >> 11472351

Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the PML-RAR alpha isoforms: a study of the PETHEMA group.

M González1, E Barragán, P Bolufer, C Chillón, D Colomer, R Borstein, M J Calasanz, M T Gómez-Casares, A Villegas, I Marugán, J Román, G Martín, C Rayón, G Debén, M Tormo, J Díaz-Mediavilla, J Esteve, J González-San Miguel, C Rivas, K Pérez-Equiza, R García-Sanz, F J Capote, J M Ribera, J Arias, A León, M A Sanz.   

Abstract

Of 167 newly diagnosed acute promyelocytic leukaemia patients, 83 patients were long (L)-form (50%), eight variable (V)-form (5%) and 76 short (S)-form (45%). The V-form and S-form groups presented a significantly higher percentage of patients with white blood cell counts > 10 x 10(9)/l (P < 0.05). The S-form cases displayed a significantly higher number of cases with M3v microgranular features (P = 0.005) and CD34 expression (P < 0.0001). There were no differences between the three isoforms in complete remission (CR) rate (overall CR 90%), but the 3-year disease-free survival was lower for V-form cases than it was for L- and S-form cases (62% vs. 94% and 89%, P = 0.056). We conclude that the V-form and S-form types are associated with some negative prognostic features at diagnosis. However, our data were only able to demonstrate an association with adverse prognosis in the V-form type and, moreover, as the number of cases was limited, needs to be confirmed in large, uniformly treated series.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472351     DOI: 10.1046/j.1365-2141.2001.02915.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  5 in total

Review 1.  New advances in the treatment of acute promyelocytic leukemia.

Authors:  Dan Douer
Journal:  Int J Hematol       Date:  2002-08       Impact factor: 2.490

2.  Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).

Authors:  Inaam Bashir Hassan; Mariam R Al Zaabi; Arif Alam; Mohammed Jawad Hashim; Martin S Tallman; Jorgen Kristensen
Journal:  Int J Hematol       Date:  2017-03-14       Impact factor: 2.490

3.  Distribution of Different PML/RARα bcr Isoforms in Indian Acute Promyelocytic Leukemia (APL) Patients and Clinicohematological Correlation.

Authors:  Tathagata Chatterjee; Srishti Gupta; Sanjeevan Sharma; Prosenjit Ganguli
Journal:  Mediterr J Hematol Infect Dis       Date:  2014-01-02       Impact factor: 2.576

4.  Pediatric Acute Promyelocytic Leukemia: Epidemiology, Molecular Features, and Importance of GST-Theta 1 in Chemotherapy Response and Outcome.

Authors:  Francianne G Andrade; Suellen V M Feliciano; Ingrid Sardou-Cezar; Gisele D Brisson; Filipe V Dos Santos-Bueno; Danielle T Vianna; Luísa V C Marques; Eugênia Terra-Granado; Ilana Zalcberg; Marceli de O Santos; Juliana T Costa; Elda P Noronha; Luiz C S Thuler; Joseph L Wiemels; Maria S Pombo-de-Oliveira
Journal:  Front Oncol       Date:  2021-03-19       Impact factor: 6.244

Review 5.  Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene.

Authors:  Alessandro Liquori; Mariam Ibañez; Claudia Sargas; Miguel Ángel Sanz; Eva Barragán; José Cervera
Journal:  Cancers (Basel)       Date:  2020-03-08       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.